salmeterol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	2419	89365-50-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: serevent salmeterol salmeterol xinafoate	Salmeterol is a selective long acting beta2-adrenoceptor agonist. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness. It has received approval to be used in combination with fluticasone. Molecular weight: 415.57 Formula: C25H37NO4 CLOGP: 3.06 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 81.95 ALOGS: -5.26 ROTB: 16 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

serevent
salmeterol
salmeterol xinafoate

Salmeterol is a selective long acting beta2-adrenoceptor agonist. In vitro studies show salmeterol to be at least 50 times more selective for beta2-adrenoceptors than albuterol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that salmeterol is a potent and long-lasting inhibitor of the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from human lung. Salmeterol inhibits histamine-induced plasma protein extravasation and inhibits platelet-activating factor-induced eosinophil accumulation in the lungs of guinea pigs when administered by the inhaled route. In humans, single doses of salmeterol administered via inhalation aerosol attenuate allergen-induced bronchial hyper-responsiveness. It has received approval to be used in combination with fluticasone.

Molecular weight: 415.57
Formula: C25H37NO4
CLOGP: 3.06
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 81.95
ALOGS: -5.26
ROTB: 16

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	mg	Inhal.aerosol
0.10	mg	Inhal.powder

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
March 26, 2021	EMA	TEVA B.V.
Feb. 4, 1994	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	2780.95	9.92	1924	92524	89618	46501996
Wheezing	874.56	9.92	781	93667	52605	46539009
Chronic obstructive pulmonary disease	680.28	9.92	704	93744	56929	46534685
Dyspnoea	662.37	9.92	2411	92037	513137	46078477
Obstructive airways disorder	382.42	9.92	272	94176	13140	46578474
Cough	368.61	9.92	1162	93286	229087	46362527
Forced expiratory volume decreased	350.71	9.92	182	94266	4922	46586692
Productive cough	348.61	9.92	470	93978	50245	46541369
Sputum discoloured	290.08	9.92	226	94222	12552	46579062
Completed suicide	245.20	9.92	12	94436	145908	46445706
Pneumonia	228.19	9.92	1419	93029	374901	46216713
Chest discomfort	223.33	9.92	535	93913	89734	46501880
Bronchitis	190.76	9.92	558	93890	105421	46486193
Temperature regulation disorder	178.40	9.92	101	94347	3259	46588355
Product quality issue	172.17	9.92	280	94168	35368	46556246
Eosinophilic granulomatosis with polyangiitis	163.22	9.92	78	94370	1758	46589856
Toxicity to various agents	152.42	9.92	123	94325	211643	46379971
Blood count abnormal	148.36	9.92	182	94266	17696	46573918
Food allergy	143.15	9.92	116	94332	6817	46584797
Middle insomnia	130.04	9.92	126	94322	9389	46582225
Immunodeficiency	124.57	9.92	143	94305	12963	46578651
Upper respiratory tract infection	124.35	9.92	345	94103	63211	46528403
Coeliac disease	123.49	9.92	108	94340	7053	46584561
Malaise	121.34	9.92	1110	93338	330122	46261492
Infective pulmonary exacerbation of cystic fibrosis	116.61	9.92	126	94322	10681	46580933
Breath sounds abnormal	111.55	9.92	106	94342	7709	46583905
Nasal congestion	105.02	9.92	272	94176	47841	46543773
Dyspnoea exertional	100.35	9.92	275	94173	50014	46541600
Lower respiratory tract infection	99.91	9.92	291	94157	54798	46536816
Dysphonia	97.40	9.92	230	94218	38184	46553430
Drug abuse	95.44	9.92	9	94439	63399	46528215
Treatment failure	94.55	9.92	35	94413	93052	46498562
Off label use	93.55	9.92	423	94025	379418	46212196
Neutropenia	91.24	9.92	93	94355	143111	46448503
Synovitis	86.02	9.92	11	94437	61064	46530550
Lung disorder	85.60	9.92	236	94212	43068	46548546
Blood immunoglobulin E increased	85.34	9.92	50	94398	1723	46589891
Influenza	84.24	9.92	381	94067	88889	46502725
Febrile neutropenia	82.85	9.92	44	94404	94583	46497031
Respiratory tract congestion	82.64	9.92	115	94333	12649	46578965
Sinusitis	82.38	9.92	496	93952	129272	46462342
Pulmonary function test decreased	76.94	9.92	63	94385	3757	46587857
Intentional overdose	75.71	9.92	19	94429	64925	46526689
Nasal polyps	72.80	9.92	49	94399	2161	46589453
Pancytopenia	70.94	9.92	42	94406	85016	46506598
Thrombocytopenia	64.08	9.92	98	94350	126483	46465131
Eosinophil count increased	63.52	9.92	79	94369	7787	46583827
Heart rate increased	63.08	9.92	309	94139	74482	46517132
Oxygen saturation decreased	62.86	9.92	292	94156	68872	46522742
Sleep disorder due to a general medical condition	62.81	9.92	54	94394	3445	46588169
Forced vital capacity decreased	61.32	9.92	32	94416	875	46590739
Bronchospasm	60.91	9.92	112	94336	15595	46576019
Bursitis	60.61	9.92	128	94320	19714	46571900
Rash erythematous	59.92	9.92	179	94269	34171	46557443
Nasopharyngitis	59.72	9.92	523	93925	153475	46438139
Malignant neoplasm progression	58.60	9.92	29	94419	64897	46526717
Hand deformity	57.52	9.92	3	94445	34571	46557043
Hypersensitivity	57.50	9.92	509	93939	149812	46441802
Asthmatic crisis	56.57	9.92	36	94412	1442	46590172
Emphysema	56.27	9.92	80	94368	8974	46582640
Systemic lupus erythematosus	56.04	9.92	31	94417	65149	46526465
Secretion discharge	55.16	9.92	80	94368	9139	46582475
Oropharyngeal pain	54.59	9.92	295	94153	73873	46517741
Fluid retention	54.35	9.92	226	94222	50820	46540794
Rales	53.92	9.92	81	94367	9550	46582064
Asphyxia	53.82	9.92	60	94388	5266	46586348
Rheumatoid arthritis	53.49	9.92	277	94171	239938	46351676
Peak expiratory flow rate decreased	53.49	9.92	26	94422	609	46591005
Haemoptysis	53.01	9.92	144	94304	26045	46565569
Seasonal allergy	52.87	9.92	96	94352	13238	46578376
Bronchial wall thickening	52.44	9.92	28	94420	803	46590811
Therapeutic product effect incomplete	51.66	9.92	302	94146	77851	46513763
Hypoventilation	49.83	9.92	51	94397	4059	46587555
Bronchiectasis	48.84	9.92	76	94372	9240	46582374
Drug ineffective	47.72	9.92	1028	93420	676810	45914804
Rhinorrhoea	47.62	9.92	207	94241	47458	46544156
Eye pruritus	47.60	9.92	86	94362	11812	46579802
Asthma-chronic obstructive pulmonary disease overlap syndrome	47.23	9.92	22	94426	467	46591147
Inhalation therapy	46.65	9.92	13	94435	53	46591561
Drug intolerance	46.28	9.92	148	94300	146901	46444713
Status asthmaticus	44.01	9.92	26	94422	910	46590704
Lung neoplasm malignant	43.97	9.92	97	94351	15392	46576222
Cystic fibrosis	43.33	9.92	45	94403	3643	46587971
Prolonged expiration	42.62	9.92	19	94429	363	46591251
Anaemia	41.96	9.92	324	94124	255455	46336159
Death	41.66	9.92	456	93992	335092	46256522
Alopecia	40.97	9.92	179	94269	162235	46429379
Blood pressure systolic increased	40.19	9.92	139	94309	28648	46562966
Rhinitis allergic	39.96	9.92	59	94389	6849	46584765
Smoke sensitivity	38.93	9.92	16	94432	248	46591366
Reversible airways obstruction	38.69	9.92	20	94428	536	46591078
Adrenal insufficiency	38.17	9.92	83	94365	13041	46578573
Aphonia	37.78	9.92	62	94386	7883	46583731
Sputum retention	37.65	9.92	18	94430	406	46591208
Rhonchi	37.38	9.92	33	94415	2182	46589432
Increased viscosity of bronchial secretion	37.01	9.92	16	94432	283	46591331
Respiratory tract infection	36.98	9.92	139	94309	29833	46561781
Increased upper airway secretion	36.92	9.92	39	94409	3220	46588394
Maternal exposure during pregnancy	36.78	9.92	97	94351	102452	46489162
Diarrhoea	35.53	9.92	862	93586	558740	46032874
Glossodynia	35.47	9.92	23	94425	44350	46547264
Leukopenia	35.45	9.92	52	94396	68291	46523323
Alanine aminotransferase increased	35.40	9.92	79	94369	88372	46503242
White blood cell count decreased	34.57	9.92	114	94334	112117	46479497
Respiratory rate increased	34.05	9.92	73	94375	11360	46580254
Lung hyperinflation	33.98	9.92	24	94424	1145	46590469
Infective exacerbation of chronic obstructive airways disease	33.78	9.92	24	94424	1156	46590458
Respiratory symptom	33.26	9.92	30	94418	2040	46589574
Pulmonary mass	33.00	9.92	95	94353	17762	46573852
Eosinophil count abnormal	32.94	9.92	17	94431	454	46591160
Rhinitis	32.72	9.92	58	94390	7848	46583766
Spirometry abnormal	32.51	9.92	13	94435	187	46591427
Joint swelling	32.33	9.92	200	94248	165873	46425741
Oral candidiasis	32.14	9.92	93	94355	17439	46574175
Lower respiratory tract congestion	31.95	9.92	28	94420	1833	46589781
Hepatotoxicity	31.81	9.92	6	94442	25003	46566611
Acute respiratory failure	31.79	9.92	130	94318	29008	46562606
Contraindicated product administered	30.71	9.92	73	94375	79874	46511740
Eosinophilic pneumonia chronic	30.69	9.92	10	94438	76	46591538
Platelet count decreased	30.53	9.92	102	94346	99922	46491692
Serotonin syndrome	30.41	9.92	6	94442	24214	46567400
Humidity intolerance	30.19	9.92	15	94433	369	46591245
Nocturnal dyspnoea	29.96	9.92	21	94427	990	46590624
Respiratory disorder	29.94	9.92	122	94326	27178	46564436
Arthropathy	29.70	9.92	81	94367	84619	46506995
Atopy	29.62	9.92	12	94436	179	46591435
Pulmonary function test abnormal	29.59	9.92	23	94425	1272	46590342
C-reactive protein abnormal	29.54	9.92	4	94444	21266	46570348
Bronchial disorder	29.51	9.92	21	94427	1014	46590600
Aspartate aminotransferase increased	29.33	9.92	73	94375	78627	46512987
Sensitivity to weather change	28.91	9.92	45	94403	5471	46586143
Sputum purulent	28.49	9.92	19	94429	825	46590789
Upper-airway cough syndrome	27.99	9.92	54	94394	7793	46583821
Coma	27.79	9.92	47	94401	58302	46533312
Viral infection	27.71	9.92	128	94320	30107	46561507
Nasal discharge discolouration	27.33	9.92	23	94425	1425	46590189
Neurosensory hypoacusis	27.08	9.92	13	94435	296	46591318
Gastrooesophageal reflux disease	26.99	9.92	249	94199	74095	46517519
Device expulsion	26.88	9.92	11	94437	27531	46564083
Musculoskeletal stiffness	26.56	9.92	105	94343	97888	46493726
Throat irritation	26.23	9.92	122	94326	28779	46562835
Hypercapnia	26.03	9.92	39	94409	4587	46587027
Total lung capacity decreased	26.00	9.92	20	94428	1089	46590525
Infusion related reaction	25.84	9.92	111	94337	101097	46490517
Sneezing	25.72	9.92	70	94378	12671	46578943
Magnetic resonance imaging thoracic abnormal	25.43	9.92	7	94441	27	46591587
Body temperature decreased	25.42	9.92	72	94376	13337	46578277
C-reactive protein increased	25.40	9.92	50	94398	58540	46533074
Therapeutic product effect decreased	25.37	9.92	84	94364	82517	46509097
Disease progression	25.27	9.92	97	94351	91203	46500411
Eosinophilic oesophagitis	25.17	9.92	11	94437	200	46591414
Total lung capacity increased	25.11	9.92	17	94431	757	46590857
Cardio-respiratory arrest	24.34	9.92	53	94395	59816	46531798
Perfume sensitivity	24.30	9.92	15	94433	569	46591045
Red blood cell sedimentation rate increased	24.27	9.92	8	94440	22881	46568733
Chest pain	23.99	9.92	495	93953	175829	46415785
Eye infection bacterial	23.98	9.92	9	94439	108	46591506
Lactic acidosis	23.96	9.92	20	94428	33889	46557725
Hyposmia	23.85	9.92	13	94435	389	46591225
Cytomegalovirus infection	23.85	9.92	4	94444	18140	46573474
Laryngitis	23.84	9.92	56	94392	9260	46582354
Dizziness	23.63	9.92	876	93572	339538	46252076
Bronchial neoplasm	23.42	9.92	11	94437	238	46591376
Rash	23.42	9.92	546	93902	355966	46235648
Increased bronchial secretion	23.24	9.92	22	94426	1592	46590022
Urticaria	23.20	9.92	351	94097	117541	46474073
Dust allergy	23.09	9.92	14	94434	514	46591100
Nasal turbinate hypertrophy	23.06	9.92	13	94435	416	46591198
Lung diffusion test decreased	22.87	9.92	15	94433	633	46590981
Bronchial haemorrhage	22.83	9.92	12	94436	333	46591281
Lipohypertrophy	22.79	9.92	16	94432	756	46590858
Neutrophil count decreased	22.56	9.92	33	94415	43393	46548221
Product use in unapproved indication	22.44	9.92	100	94348	90173	46501441
Influenza B virus test positive	22.17	9.92	12	94436	354	46591260
Arteriosclerosis coronary artery	21.94	9.92	50	94398	8106	46583508
Sputum increased	21.67	9.92	22	94426	1734	46589880
Hyperhidrosis	21.67	9.92	276	94172	89032	46502582
Immune-mediated pancreatitis	21.62	9.92	7	94441	52	46591562
Drug reaction with eosinophilia and systemic symptoms	21.41	9.92	17	94431	29531	46562083
Eosinophilic bronchitis	21.41	9.92	11	94437	291	46591323
Disseminated intravascular coagulation	21.31	9.92	6	94442	18999	46572615
Hepatic function abnormal	21.17	9.92	23	94425	34398	46557216
Multiple organ dysfunction syndrome	20.84	9.92	46	94402	51664	46539950
Headache	20.80	9.92	1174	93274	477178	46114436
Throat clearing	20.73	9.92	12	94436	404	46591210
Cortisol decreased	20.57	9.92	17	94431	1027	46590587
Paranasal sinus discomfort	20.56	9.92	26	94422	2606	46589008
Decreased bronchial secretion	20.45	9.92	7	94441	63	46591551
Heart sounds	20.24	9.92	10	94438	243	46591371
Palmar-plantar erythrodysaesthesia syndrome	20.23	9.92	8	94440	20443	46571171
Restrictive pulmonary disease	20.16	9.92	18	94430	1208	46590406
Hepatic failure	19.82	9.92	23	94425	33393	46558221
Sinus congestion	19.80	9.92	65	94383	13044	46578570
Respiration abnormal	19.79	9.92	34	94414	4487	46587127
Neoplasm progression	19.78	9.92	15	94433	26668	46564946
Suicide attempt	19.77	9.92	52	94396	54984	46536630
Accidental exposure to product	19.65	9.92	9	94439	21072	46570542
Respiratory arrest	19.28	9.92	24	94424	33792	46557822
Exposure during pregnancy	19.18	9.92	134	94314	108078	46483536
Bone marrow failure	19.18	9.92	19	94429	29650	46561964
Septic shock	19.09	9.92	57	94391	57836	46533778
Weight decreased	19.08	9.92	560	93888	210289	46381325
Bronchial obstruction	19.00	9.92	18	94430	1304	46590310
Encephalopathy	18.98	9.92	24	94424	33565	46558049
Conjunctivitis allergic	18.95	9.92	14	94434	717	46590897
Choking	18.93	9.92	48	94400	8328	46583286
Functional residual capacity increased	18.73	9.92	7	94441	83	46591531
Perineal fistula	18.72	9.92	6	94442	43	46591571
Hypotension	18.56	9.92	345	94103	232244	46359370
Seizure	18.26	9.92	160	94288	122894	46468720
Cognitive disorder	18.22	9.92	29	94419	36854	46554760
Dyskinesia	18.15	9.92	19	94429	28906	46562708
Premature baby	18.06	9.92	7	94441	18105	46573509
Bronchial secretion retention	17.84	9.92	15	94433	928	46590686
Bronchitis chronic	17.80	9.92	31	94417	4136	46587478
Acute hepatic failure	17.75	9.92	4	94444	14717	46576897
Intentional self-injury	17.39	9.92	14	94434	24152	46567462
Bradycardia	17.35	9.92	72	94376	66226	46525388
Thyroid atrophy	17.29	9.92	5	94443	24	46591590
Renal failure	17.16	9.92	147	94301	113447	46478167
Oropharyngitis fungal	17.15	9.92	6	94442	58	46591556
Impaired healing	17.12	9.92	30	94418	36713	46554901
Fungal endocarditis	17.12	9.92	9	94439	250	46591364
Product administration error	17.07	9.92	82	94366	19599	46572015
Ascites	16.93	9.92	30	94418	36554	46555060
Sarcoidosis	16.59	9.92	34	94414	5125	46586489
Drug interaction	16.59	9.92	300	94148	202794	46388820
Aspirin-exacerbated respiratory disease	16.47	9.92	13	94435	735	46590879
Peak expiratory flow rate abnormal	16.45	9.92	7	94441	119	46591495
Anaphylactic reaction	16.39	9.92	172	94276	52940	46538674
Otorrhoea	16.20	9.92	17	94431	1393	46590221
Stomatitis	16.17	9.92	77	94371	68220	46523394
Back pain	16.14	9.92	547	93901	209492	46382122
Sepsis	15.97	9.92	187	94261	135827	46455787
Hyperkalaemia	15.96	9.92	51	94397	50658	46540956
Functional residual capacity decreased	15.91	9.92	6	94442	73	46591541
Granuloma	15.89	9.92	28	94420	3770	46587844
Trifascicular block	15.88	9.92	7	94441	130	46591484
Dysmetropsia	15.77	9.92	6	94442	75	46591539
Adrenal suppression	15.71	9.92	14	94434	937	46590677
Pulmonary pain	15.44	9.92	18	94430	1658	46589956
Drug resistance	15.30	9.92	8	94440	17360	46574254
Shock	15.29	9.92	13	94435	21832	46569782
Type 2 diabetes mellitus	15.25	9.92	80	94368	19795	46571819
Plasma cell myeloma	15.24	9.92	43	94405	44435	46547179
Respiratory tract irritation	15.16	9.92	10	94438	426	46591188
Abdominal discomfort	15.11	9.92	215	94233	150950	46440664
Blood test abnormal	15.10	9.92	48	94400	9472	46582142
Pneumocystis jirovecii pneumonia	15.03	9.92	6	94442	15242	46576372
Vital capacity decreased	14.98	9.92	11	94437	558	46591056
Psoriatic arthropathy	14.95	9.92	32	94416	36347	46555267
Peritonitis	14.90	9.92	12	94436	20702	46570912
Sopor	14.89	9.92	11	94437	19817	46571797
Bronchitis bacterial	14.88	9.92	12	94436	700	46590914
Dehydration	14.87	9.92	230	94218	159310	46432304
Blood creatinine increased	14.85	9.92	92	94356	76311	46515303
Chronic sinusitis	14.83	9.92	32	94416	5001	46586613
Exposure to allergen	14.80	9.92	7	94441	154	46591460
Nasal oedema	14.73	9.92	13	94435	859	46590755
Generalised tonic-clonic seizure	14.69	9.92	20	94428	27102	46564512
Poisoning	14.64	9.92	5	94443	13989	46577625
Mucosal inflammation	14.64	9.92	36	94412	38940	46552674
Eczema impetiginous	14.62	9.92	4	94444	15	46591599
Pneumonia aspiration	14.55	9.92	26	94422	31579	46560035
Metastases to liver	14.53	9.92	11	94437	19574	46572040
Nasal mucosal discolouration	14.42	9.92	4	94444	16	46591598
Premature delivery	14.42	9.92	14	94434	22055	46569559
Bronchopulmonary aspergillosis allergic	14.39	9.92	12	94436	734	46590880
Small airways disease	14.22	9.92	4	94444	17	46591597
Allergy to animal	14.17	9.92	11	94437	607	46591007
Investigation	14.15	9.92	17	94431	1617	46589997
Hyperplastic cholecystopathy	14.10	9.92	6	94442	102	46591512
Breast conserving surgery	13.78	9.92	12	94436	779	46590835
Nasal mucosal disorder	13.53	9.92	9	94439	389	46591225
Tobacco abuse	13.42	9.92	11	94437	657	46590957
Chronic respiratory failure	13.26	9.92	17	94431	1727	46589887
Nasal obstruction	13.25	9.92	11	94437	669	46590945
Foetal malnutrition	13.21	9.92	6	94442	120	46591494
Eosinophilia	13.17	9.92	75	94373	19142	46572472
Endometrial ablation	12.97	9.92	11	94437	689	46590925
Acute myeloid leukaemia	12.85	9.92	8	94440	15770	46575844
Myelodysplastic syndrome	12.75	9.92	8	94440	15703	46575911
Infective aneurysm	12.75	9.92	9	94439	429	46591185
Osteonecrosis of jaw	12.74	9.92	32	94416	34370	46557244
Foetal exposure during pregnancy	12.68	9.92	27	94421	30720	46560894
Psoriasis	12.65	9.92	100	94348	78504	46513110
Pericarditis	12.60	9.92	18	94430	23909	46567705
Varicella zoster oesophagitis	12.56	9.92	4	94444	28	46591586
Injection site reaction	12.50	9.92	52	94396	47797	46543817
Drug ineffective for unapproved indication	12.46	9.92	9	94439	16404	46575210
Gait deviation	12.38	9.92	5	94443	74	46591540
Adverse drug reaction	12.36	9.92	47	94401	44315	46547299
Haemoglobin decreased	12.32	9.92	185	94263	128764	46462850
Faecal volume decreased	12.17	9.92	6	94442	145	46591469
Gamma-glutamyltransferase increased	12.17	9.92	29	94419	31711	46559903
Palpitations	12.15	9.92	265	94183	94994	46496620
Muscle spasticity	12.12	9.92	4	94444	11436	46580178
Osteochondritis	12.10	9.92	4	94444	32	46591582
Breast neoplasm	12.08	9.92	14	94434	1281	46590333
Varicella zoster gastritis	11.99	9.92	4	94444	33	46591581
Liver injury	11.85	9.92	9	94439	15992	46575622
Crepitations	11.83	9.92	33	94415	6059	46585555
Sputum abnormal	11.82	9.92	8	94440	356	46591258
Sinus headache	11.75	9.92	28	94420	4672	46586942
Hypothermia	11.67	9.92	5	94443	12178	46579436
Abortion spontaneous	11.67	9.92	47	94401	43599	46548015
Neuroleptic malignant syndrome	11.59	9.92	4	94444	11118	46580496
Illness	11.38	9.92	52	94396	12172	46579442
Stress fracture	11.36	9.92	36	94412	7091	46584523
Gastroenteritis eosinophilic	11.29	9.92	5	94443	94	46591520
Pneumonectomy	11.24	9.92	3	94445	10	46591604
Haemolytic anaemia	11.23	9.92	3	94445	9839	46581775
Blood lactate dehydrogenase increased	11.22	9.92	15	94433	20485	46571129
Symptom recurrence	11.21	9.92	8	94440	388	46591226
Influenza like illness	11.16	9.92	171	94277	57399	46534215
No adverse event	11.07	9.92	34	94414	34197	46557417
Depressed level of consciousness	11.04	9.92	54	94394	47515	46544099
Bronchospasm paradoxical	10.96	9.92	5	94443	101	46591513
Overdose	10.92	9.92	143	94305	101836	46489778
Transplant rejection	10.81	9.92	3	94445	9593	46582021
Tracheobronchitis bacterial	10.81	9.92	3	94445	12	46591602
Cerebral haemorrhage	10.81	9.92	26	94422	28345	46563269
Infusion site erythema	10.75	9.92	37	94411	7605	46584009
Throat tightness	10.69	9.92	75	94373	20564	46571050
Mydriasis	10.65	9.92	4	94444	10549	46581065
FEV1/FVC ratio decreased	10.62	9.92	3	94445	13	46591601
Nasal pruritus	10.62	9.92	7	94441	298	46591316
Peroneal nerve injury	10.51	9.92	4	94444	50	46591564
Candida infection	10.47	9.92	79	94369	22161	46569453
Renal impairment	10.46	9.92	98	94350	74274	46517340
Nausea	10.44	9.92	1225	93223	686229	45905385
Cor pulmonale	10.39	9.92	16	94432	1927	46589687
Drug eruption	10.32	9.92	17	94431	21312	46570302
Blood pressure fluctuation	10.02	9.92	30	94418	30418	46561196
Bacillus infection	9.99	9.92	7	94441	330	46591284
Erythema	9.98	9.92	368	94080	142452	46449162
Ejection fraction decreased	9.95	9.92	13	94435	17924	46573690

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	1647.26	10.81	913	48346	35261	29867958
Chronic obstructive pulmonary disease	635.73	10.81	559	48700	45567	29857652
Wheezing	527.29	10.81	424	48835	30514	29872705
Dyspnoea	398.88	10.81	1325	47934	331970	29571249
Obstructive airways disorder	390.35	10.81	221	49038	8838	29894381
Cough	269.63	10.81	620	48639	125022	29778197
Sputum discoloured	253.54	10.81	150	49109	6518	29896701
Forced expiratory volume decreased	243.38	10.81	115	49144	3135	29900084
Productive cough	228.94	10.81	264	48995	29689	29873530
Blood count abnormal	184.20	10.81	153	49106	11499	29891720
Eosinophilic granulomatosis with polyangiitis	172.14	10.81	69	49190	1246	29901973
Toxicity to various agents	157.43	10.81	48	49211	177135	29726084
Pneumonia	155.61	10.81	1009	48250	333297	29569922
Pulmonary function test decreased	131.10	10.81	84	49175	4211	29899008
Infective pulmonary exacerbation of cystic fibrosis	128.13	10.81	109	49150	8463	29894756
Bronchiectasis	114.19	10.81	83	49176	5121	29898098
Completed suicide	110.64	10.81	16	49243	99476	29803743
Nasal congestion	108.46	10.81	143	49116	18423	29884796
Chest discomfort	107.95	10.81	234	49025	45246	29857973
Lower respiratory tract infection	104.13	10.81	170	49089	26544	29876675
Therapeutic product effect incomplete	102.88	10.81	193	49066	33641	29869578
Asthma-chronic obstructive pulmonary disease overlap syndrome	101.27	10.81	39	49220	630	29902589
Nasal obstruction	100.54	10.81	39	49220	643	29902576
Product quality issue	95.15	10.81	135	49124	18639	29884580
Respiratory tract congestion	86.38	10.81	72	49187	5434	29897785
Blood immunoglobulin E increased	84.88	10.81	46	49213	1684	29901535
Bronchitis	83.51	10.81	193	49066	38932	29864287
Respiratory disorder	78.81	10.81	119	49140	17375	29885844
Sinus pain	75.96	10.81	32	49227	659	29902560
Nasal polyps	74.23	10.81	39	49220	1340	29901879
Emphysema	73.67	10.81	84	49175	9318	29893901
Sinusitis	70.62	10.81	164	49095	33181	29870038
Nasopharyngitis	70.45	10.81	235	49024	58614	29844605
Breath sounds abnormal	68.17	10.81	60	49199	4875	29898344
Middle insomnia	63.86	10.81	62	49197	5711	29897508
Respiratory rate increased	63.76	10.81	76	49183	8839	29894380
Dyspnoea exertional	63.06	10.81	163	49096	35267	29867952
Drug abuse	63.05	10.81	28	49231	82044	29821175
Painful respiration	59.65	10.81	33	49226	1259	29901960
Hypoventilation	59.12	10.81	45	49214	2978	29900241
Malaise	58.68	10.81	472	48787	166490	29736729
Thrombocytopenia	56.72	10.81	86	49173	136958	29766261
Febrile neutropenia	55.65	10.81	56	49203	106637	29796582
Dust allergy	54.99	10.81	22	49237	395	29902824
Sleep disorder due to a general medical condition	54.92	10.81	33	49226	1474	29901745
Mycobacterium avium complex infection	54.44	10.81	41	49218	2670	29900549
Status asthmaticus	52.98	10.81	20	49239	305	29902914
Nasal disorder	51.58	10.81	29	49230	1142	29902077
Sensitivity to weather change	50.83	10.81	31	49228	1423	29901796
Pulmonary mass	50.50	10.81	75	49184	10787	29892432
Heart rate increased	50.26	10.81	159	49100	38562	29864657
Inhalation therapy	50.25	10.81	12	49247	29	29903190
Pulmonary function test abnormal	49.41	10.81	30	49229	1366	29901853
Throat irritation	47.09	10.81	64	49195	8484	29894735
Influenza	45.58	10.81	166	49093	43232	29859987
Body temperature decreased	45.37	10.81	67	49192	9588	29893631
Osteopenia	44.22	10.81	46	49213	4602	29898617
Respiratory tract infection	42.87	10.81	85	49174	15421	29887798
Restrictive pulmonary disease	42.83	10.81	25	49234	1058	29902161
Infective exacerbation of chronic obstructive airways disease	40.78	10.81	27	49232	1431	29901788
Platelet count decreased	40.69	10.81	70	49189	106059	29797160
Oxygen saturation decreased	39.73	10.81	159	49100	43281	29859938
Off label use	39.64	10.81	244	49015	249046	29654173
Asthmatic crisis	39.26	10.81	18	49241	457	29902762
Foetal malformation	38.62	10.81	13	49246	139	29903080
Renal impairment	37.60	10.81	50	49209	84134	29819085
Eosinophil count increased	36.77	10.81	53	49206	7420	29895799
Lower respiratory tract congestion	36.44	10.81	22	49237	991	29902228
Walking aid user	36.18	10.81	25	49234	1422	29901797
Increased viscosity of bronchial secretion	36.13	10.81	14	49245	230	29902989
Blood pressure systolic increased	34.96	10.81	77	49182	15033	29888186
Neutropenia	34.46	10.81	103	49156	128437	29774782
Central obesity	33.55	10.81	17	49242	541	29902678
Mite allergy	33.20	10.81	13	49246	220	29902999
Bronchial hyperreactivity	33.06	10.81	22	49237	1176	29902043
Chest injury	32.78	10.81	23	49236	1341	29901878
Trisomy 18	32.67	10.81	13	49246	230	29902989
Granulomatous rosacea	32.53	10.81	12	49247	171	29903048
Lung diffusion test decreased	32.17	10.81	17	49242	591	29902628
Cystic fibrosis	32.12	10.81	28	49231	2246	29900973
Adrenal suppression	31.53	10.81	17	49242	616	29902603
Pancytopenia	30.89	10.81	58	49201	84994	29818225
Blood pressure increased	30.66	10.81	213	49046	71715	29831504
Rhabdomyolysis	30.22	10.81	36	49223	63544	29839675
Oral candidiasis	29.78	10.81	60	49199	11011	29892208
Nasal discharge discolouration	29.52	10.81	12	49247	225	29902994
Lung hyperinflation	29.40	10.81	18	49241	832	29902387
Intentional overdose	29.04	10.81	16	49243	41465	29861754
Death	28.93	10.81	414	48845	356869	29546350
Cerebral artery thrombosis	28.80	10.81	15	49244	506	29902713
Sputum increased	28.54	10.81	24	49235	1833	29901386
Diarrhoea	28.52	10.81	383	48876	333720	29569499
Brain scan abnormal	28.30	10.81	16	49243	637	29902582
Bronchial wall thickening	27.84	10.81	14	49245	438	29902781
Reversible airways obstruction	27.63	10.81	12	49247	267	29902952
Blood immunoglobulin E decreased	27.13	10.81	8	49251	53	29903166
Rhinitis	24.91	10.81	34	49225	4525	29898694
Sputum purulent	24.89	10.81	13	49246	441	29902778
Bone marrow failure	24.75	10.81	9	49250	29776	29873443
Stress	24.36	10.81	81	49178	20154	29883065
Upper-airway cough syndrome	24.32	10.81	26	49233	2684	29900535
Lung consolidation	24.18	10.81	35	49224	4917	29898302
White blood cell count decreased	24.15	10.81	65	49194	83882	29819337
Aspartate aminotransferase increased	24.14	10.81	42	49217	63380	29839839
Hepatic failure	24.02	10.81	13	49246	34030	29869189
Hepatic haematoma	24.01	10.81	13	49246	475	29902744
Transposition of the great vessels	23.91	10.81	13	49246	479	29902740
Rhonchi	23.84	10.81	21	49238	1708	29901511
Respiratory tract irritation	23.62	10.81	9	49250	141	29903078
Rales	23.48	10.81	40	49219	6460	29896759
Alanine aminotransferase increased	23.31	10.81	55	49204	74221	29828998
Forced vital capacity decreased	23.31	10.81	15	49244	757	29902462
Multiple organ dysfunction syndrome	23.30	10.81	43	49216	63444	29839775
Blood creatinine increased	23.21	10.81	75	49184	91300	29811919
Growth retardation	23.20	10.81	20	49239	1580	29901639
Bronchospasm	23.15	10.81	52	49207	10286	29892933
Conjunctivitis allergic	22.91	10.81	13	49246	521	29902698
Sputum abnormal	22.84	10.81	12	49247	412	29902807
Dysphonia	22.74	10.81	76	49183	18956	29884263
Malignant neoplasm progression	22.31	10.81	54	49205	72233	29830986
Rhinorrhoea	22.30	10.81	80	49179	20674	29882545
Mycotic allergy	22.17	10.81	9	49250	168	29903051
Lung disorder	21.78	10.81	106	49153	31363	29871856
Respiratory symptom	20.86	10.81	14	49245	759	29902460
Blood pressure diastolic decreased	20.76	10.81	37	49222	6194	29897025
Respiratory distress	20.67	10.81	108	49151	32864	29870355
Drug resistance	20.67	10.81	4	49255	20129	29883090
Anaemia	20.50	10.81	231	49028	207761	29695458
Anosmia	20.36	10.81	21	49238	2079	29901140
Sneezing	20.29	10.81	30	49229	4297	29898922
Upper respiratory tract infection	20.07	10.81	94	49165	27382	29875837
Necrotising oesophagitis	20.04	10.81	11	49248	413	29902806
Hepatotoxicity	19.96	10.81	3	49256	18142	29885077
Sepsis	19.87	10.81	150	49109	146245	29756974
Lipohypertrophy	19.80	10.81	10	49249	316	29902903
Product use in unapproved indication	19.76	10.81	59	49200	73634	29829585
Nasal inflammation	19.57	10.81	9	49250	230	29902989
Bone deformity	19.37	10.81	6	49253	48	29903171
Eosinophilia	19.36	10.81	80	49179	22080	29881139
Weight increased	19.20	10.81	198	49061	74715	29828504
Cushingoid	19.11	10.81	22	49237	2465	29900754
Renal failure	19.02	10.81	129	49130	128837	29774382
Coma uraemic	18.95	10.81	6	49253	52	29903167
Carcinoid tumour of the gastrointestinal tract	18.95	10.81	6	49253	52	29903167
Aortic aneurysm	18.75	10.81	36	49223	6377	29896842
Aspirin-exacerbated respiratory disease	18.68	10.81	10	49249	357	29902862
Alveolar bone resorption	18.31	10.81	5	49254	24	29903195
Throat tightness	18.19	10.81	38	49221	7154	29896065
Seasonal allergy	18.17	10.81	30	49229	4723	29898496
Atopy	18.12	10.81	7	49252	114	29903105
Leukopenia	18.09	10.81	41	49218	56118	29847101
Neuropathy peripheral	17.78	10.81	58	49201	70417	29832802
Spirometry abnormal	17.68	10.81	9	49250	289	29902930
Hypopnoea	17.64	10.81	15	49244	1163	29902056
Forced expiratory flow decreased	17.58	10.81	7	49252	124	29903095
Product complaint	17.48	10.81	33	49226	5773	29897446
Ascites	17.43	10.81	20	49239	35901	29867318
Blood test abnormal	17.38	10.81	32	49227	5493	29897726
Malpositioned teeth	17.24	10.81	5	49254	31	29903188
Neutrophil count decreased	17.19	10.81	27	49232	42427	29860792
Sinus congestion	16.98	10.81	29	49230	4693	29898526
Bronchopulmonary aspergillosis allergic	16.92	10.81	9	49250	317	29902902
Eye infection	16.76	10.81	22	49237	2820	29900399
Drug-induced liver injury	16.73	10.81	7	49252	21267	29881952
Weight decreased	16.58	10.81	344	48915	150577	29752642
Peak expiratory flow rate decreased	16.58	10.81	7	49252	145	29903074
Bronchial disorder	16.55	10.81	13	49246	901	29902318
Cortisol decreased	16.50	10.81	13	49246	905	29902314
Extra dose administered	16.49	10.81	22	49237	2864	29900355
Nausea	16.38	10.81	368	48891	296589	29606630
Haemoptysis	16.28	10.81	97	49162	30981	29872238
Hepatocellular injury	16.19	10.81	11	49248	25460	29877759
Electrocardiogram QT shortened	15.98	10.81	7	49252	159	29903060
Loss of personal independence in daily activities	15.96	10.81	74	49185	21461	29881758
Polyp	15.83	10.81	23	49236	3243	29899976
Crepitations	15.69	10.81	22	49237	3002	29900217
Tubulointerstitial nephritis	15.57	10.81	5	49254	17886	29885333
Cytomegalovirus infection	15.35	10.81	10	49249	23664	29879555
Hot flush	15.27	10.81	56	49203	14624	29888595
Flour sensitivity	15.15	10.81	5	49254	50	29903169
Proteinuria	14.99	10.81	4	49255	16141	29887078
Rhinitis perennial	14.83	10.81	6	49253	111	29903108
Drug reaction with eosinophilia and systemic symptoms	14.78	10.81	15	49244	28473	29874746
Mucosal inflammation	14.77	10.81	17	49242	30477	29872742
Pneumocystis jirovecii pneumonia	14.52	10.81	5	49254	17115	29886104
Food allergy	14.50	10.81	12	49247	896	29902323
Acute respiratory failure	14.40	10.81	82	49177	25768	29877451
Cholestasis	14.29	10.81	12	49247	24938	29878281
Diffuse panbronchiolitis	14.16	10.81	3	49256	3	29903216
Aphonia	14.12	10.81	21	49238	3023	29900196
Chronic sinusitis	14.06	10.81	15	49244	1544	29901675
Neoplasm progression	14.06	10.81	6	49253	18017	29885202
Hepatic function abnormal	14.02	10.81	30	49229	41915	29861304
Peritonitis	13.90	10.81	9	49250	21366	29881853
Dehydration	13.87	10.81	133	49126	123406	29779813
Infective exacerbation of bronchiectasis	13.68	10.81	9	49250	472	29902747
Throat clearing	13.52	10.81	7	49252	233	29902986
Rhinitis allergic	13.47	10.81	20	49239	2874	29900345
Respiration abnormal	13.38	10.81	19	49240	2623	29900596
Nightmare	13.36	10.81	47	49212	12029	29891190
Spleen congestion	13.10	10.81	8	49251	368	29902851
Hypersensitivity	12.99	10.81	141	49118	53887	29849332
Increased upper airway secretion	12.85	10.81	15	49244	1705	29901514
Plasma cell myeloma	12.80	10.81	45	49214	53417	29849802
Neurotoxicity	12.75	10.81	3	49256	13179	29890040
Disease progression	12.73	10.81	78	49181	79796	29823423
Hyperbilirubinaemia	12.65	10.81	6	49253	16936	29886283
Pseudomonas infection	12.65	10.81	42	49217	10440	29892779
Acute myeloid leukaemia	12.52	10.81	7	49252	17999	29885220
Cerebral infarction	12.45	10.81	15	49244	26358	29876861
Drug intolerance	12.33	10.81	36	49223	45255	29857964
Meralgia paraesthetica	12.20	10.81	6	49253	179	29903040
Deformity thorax	12.12	10.81	4	49255	40	29903179
Dyspnoea at rest	12.12	10.81	18	49241	2588	29900631
Bronchitis bacterial	12.12	10.81	10	49249	744	29902475
Alpha-1 antitrypsin deficiency	12.09	10.81	3	49256	9	29903210
Somnambulism	11.90	10.81	20	49239	3194	29900025
Hypovolaemic shock	11.65	10.81	30	49229	6470	29896749
Acute respiratory distress syndrome	11.46	10.81	13	49246	23459	29879760
Depressed level of consciousness	11.44	10.81	29	49230	38193	29865026
Hypohidrosis	11.42	10.81	6	49253	206	29903013
Intentional product misuse	11.41	10.81	25	49234	34642	29868577
Eosinophilic bronchitis	11.39	10.81	4	49255	49	29903170
Delirium	11.27	10.81	32	49227	40599	29862620
Carcinoid tumour of the stomach	11.25	10.81	4	49255	51	29903168
Eye disorder	11.19	10.81	33	49226	7701	29895518
Vomiting	11.10	10.81	276	48983	219542	29683677
Type 2 diabetes mellitus	10.99	10.81	48	49211	13574	29889645
Hypokalaemic syndrome	10.89	10.81	3	49256	15	29903204
Ileus	10.89	10.81	6	49253	15549	29887670
Epidural lipomatosis	10.82	10.81	6	49253	230	29902989

Pharmacologic Action:

Source	Code	Description
ATC	R03AC12	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03AK06	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03AK12	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA MoA	N0000009922	Adrenergic beta2-Agonists
FDA EPC	N0000175779	beta2-Adrenergic Agonist
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:35522	beta-adrenergic receptor agonist
CHEBI has role	CHEBI:35523	bronchodilator agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Pulmonary emphysema	indication	87433001
Non-allergic asthma	indication	266361008	DOID:9360
Allergic asthma	indication	389145006	DOID:9415
Adjunct Therapy to Achieve Long-term Asthma Control	indication
Bronchospasm Prevention with COPD	indication
Exercise-Induced Bronchospasm Prevention	indication
COPD Associated with Chronic Bronchitis	indication
Mycosis	contraindication	3218000	DOID:1564
Disease caused by parasite	contraindication	17322007
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Ketoacidosis	contraindication	56051008
Osteoporosis	contraindication	64859006	DOID:11476
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Candidiasis of mouth	contraindication	79740000	DOID:14262
Hyperglycemia	contraindication	80394007	DOID:4195
Thyrotoxicosis	contraindication	90739004	DOID:7997
Bilateral cataracts	contraindication	95722004
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Ophthalmic herpes simplex	contraindication	186542001
Exacerbation of asthma	contraindication	281239006
Osteopenia	contraindication	312894000
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Congenital long QT syndrome	contraindication	442917000
Uncontrolled Bacterial Infections	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.07	acidic
pKa2	9.28	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Ki	9.41	CHEMBL	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.00	WOMBAT-PK
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	6.10	CHEMBL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		EC50	6	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.98	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		EC50	7.50	CHEMBL

External reference:

ID	Source
4023955	VUID
N0000021960	NUI
D00687	KEGG_DRUG
94749-08-3	SECONDARY_CAS_RN
4020873	VANDF
4023955	VANDF
C0245531	UMLSCUI
CHEBI:9011	CHEBI
K5Y	PDB_CHEM_ID
CHEMBL1263	ChEMBL_ID
CHEMBL1082607	ChEMBL_ID
D000068299	MESH_DESCRIPTOR_UI
559	IUPHAR_LIGAND_ID
5578	INN_ID
DB00938	DRUGBANK_ID
2I4BC502BT	UNII
5152	PUBCHEM_CID
203159	RXNORM
1605	MMSL
21564	MMSL
5440	MMSL
d03759	MMSL
004036	NDDF
004037	NDDF
108605008	SNOMEDCT_US
108606009	SNOMEDCT_US
372515005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0326	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	29 sections
fluticasone propionate and salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0054-0327	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	29 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3607	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA AUTHORIZED GENERIC	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3608	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA AUTHORIZED GENERIC	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	0093-3609	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA AUTHORIZED GENERIC	28 sections
SEREVENTDISKUS	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0520	POWDER, METERED	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
SEREVENTDISKUS	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0521	POWDER, METERED	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0695	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0696	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0697	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	27 sections
ADVAIR HFA	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0715	AEROSOL, METERED	21 ug	RESPIRATORY (INHALATION)	NDA	28 sections
ADVAIR HFA	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0716	AEROSOL, METERED	21 ug	RESPIRATORY (INHALATION)	NDA	28 sections
ADVAIR HFA	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0717	AEROSOL, METERED	21 ug	RESPIRATORY (INHALATION)	NDA	28 sections
Wixela Inhub	HUMAN PRESCRIPTION DRUG LABEL	2	0378-9320	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	30 sections
Wixela Inhub	HUMAN PRESCRIPTION DRUG LABEL	2	0378-9321	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	30 sections
Wixela Inhub	HUMAN PRESCRIPTION DRUG LABEL	2	0378-9322	POWDER	50 ug	RESPIRATORY (INHALATION)	ANDA	30 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	21695-196	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	21695-197	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	21695-361	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	33261-873	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	33261-874	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	29 sections
ADVAIRDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	50090-0731	POWDER	0.05 mg	RESPIRATORY (INHALATION)	NDA	28 sections
Fluticasone Propionate and Salmeterol	HUMAN PRESCRIPTION DRUG LABEL	2	50090-3387	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA AUTHORIZED GENERIC	28 sections
Fluticasone Propionate and SalmeterolDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	50090-4211	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA authorized generic	29 sections
Fluticasone Propionate and SalmeterolDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	50090-4213	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA authorized generic	29 sections
Fluticasone Propionate and SalmeterolDISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	50090-4214	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA authorized generic	29 sections
ADVAIR DISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	54868-4516	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
ADVAIR DISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	54868-4517	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
ADVAIR DISKUS	HUMAN PRESCRIPTION DRUG LABEL	2	54868-4518	POWDER	50 ug	RESPIRATORY (INHALATION)	NDA	30 sections
AirDuo Digihaler	HUMAN PRESCRIPTION DRUG LABEL	2	59310-111	POWDER, METERED	14 ug	RESPIRATORY (INHALATION)	NDA	28 sections